MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The ...
Jul 23, 2021
0
81
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center—Arthur ...
Jul 21, 2021
0
1
Researchers at The Australian National University (ANU) have discovered how a DNA-binding protein sustains Hodgkin lymphoma.
Jul 21, 2021
0
91
In order to grow beyond control, tumors manipulate cell signals to make it appear as if the cells have the nutrients they need. That is the case in follicular lymphoma, a type of tumor that affects the B lymphocytes of the ...
Jul 13, 2021
0
8
A new class of drugs that inhibits a 'master switch' involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai.
Jun 22, 2021
0
8
Every year, about 400,000 people receive silicone breast implants in the United States. According to data from the U.S. Food and Drug Administration, a majority of those implants needs to be replaced within 10 years due to ...
Jun 21, 2021
0
11
New research uncovers substantial differences in rates of childhood cancers when considering single year of age rather than grouping several years together. The study published by Wiley early online in Cancer, a peer-reviewed ...
Jun 21, 2021
0
1
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against ...
May 13, 2021
0
5
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...
Apr 14, 2021
0
2
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional ...
Apr 11, 2021
0
4
